Published in Diabetes on March 12, 2007
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev (2008) 2.79
Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia (2010) 2.21
Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem (2012) 2.10
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A (2007) 1.68
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Human islet amyloid polypeptide monomers form ordered beta-hairpins: a possible direct amyloidogenic precursor. J Am Chem Soc (2009) 1.46
A single mutation in the nonamyloidogenic region of islet amyloid polypeptide greatly reduces toxicity. Biochemistry (2008) 1.27
Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr Alzheimer Res (2008) 1.26
Induction of negative curvature as a mechanism of cell toxicity by amyloidogenic peptides: the case of islet amyloid polypeptide. J Am Chem Soc (2009) 1.25
The amyloid formation mechanism in human IAPP: dimers have β-strand monomer-monomer interfaces. J Am Chem Soc (2011) 1.22
Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem (2009) 1.21
Amyloidogenic peptide oligomer accumulation in autophagy-deficient β cells induces diabetes. J Clin Invest (2014) 1.17
Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in beta-cell death in type 2 diabetes mellitus. Exp Diabetes Res (2008) 1.15
Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide. FASEB J (2011) 1.14
Islets in type 2 diabetes: in honor of Dr. Robert C. Turner. Diabetes (2008) 1.11
β-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency. Diabetes (2010) 1.10
Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes. J Biol Chem (2009) 1.08
The molecular basis of distinct aggregation pathways of islet amyloid polypeptide. J Biol Chem (2010) 1.01
Phosphatidylethanolamine enhances amyloid fiber-dependent membrane fragmentation. Biochemistry (2012) 0.95
The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity. Amyloid (2010) 0.92
Exploring the influence of carbon nanoparticles on the formation of β-sheet-rich oligomers of IAPP₂₂₋₂₈ peptide by molecular dynamics simulation. PLoS One (2013) 0.88
Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides. PLoS Comput Biol (2013) 0.86
Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions. J Am Chem Soc (2014) 0.86
Cleavage agents for soluble oligomers of human islet amyloid polypeptide. J Biol Inorg Chem (2008) 0.86
Fiber-dependent and -independent toxicity of islet amyloid polypeptide. Biophys J (2014) 0.82
X-ray Crystallographic Structures of Oligomers of Peptides Derived from β2-Microglobulin. J Am Chem Soc (2015) 0.81
Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity. Biochemistry (2009) 0.81
Chaperones ameliorate beta cell dysfunction associated with human islet amyloid polypeptide overexpression. PLoS One (2014) 0.81
Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis (2010) 0.81
Degradation of islet amyloid polypeptide by neprilysin. Diabetologia (2012) 0.81
Involvement of ATP-sensitive potassium (K(ATP)) channels in the loss of beta-cell function induced by human islet amyloid polypeptide. J Biol Chem (2011) 0.79
New chelating ligands for Co(III)-based peptide-cleaving catalysts selective for pathogenic proteins of amyloidoses. J Biol Inorg Chem (2010) 0.78
Lessons from two prevalent amyloidoses-what amylin and Aβ have in common. Front Aging Neurosci (2013) 0.78
Dynamics of the formation of a hydrogel by a pathogenic amyloid peptide: islet amyloid polypeptide. Sci Rep (2016) 0.77
Evidence of π-stacking interactions in the self-assembly of hIAPP(22-29). Proteins (2013) 0.77
β-Cell dysfunction under hyperglycemic stress: a molecular model. J Diabetes Sci Technol (2010) 0.77
CHOP Contributes to, But Is Not the Only Mediator of, IAPP Induced β-Cell Apoptosis. Mol Endocrinol (2016) 0.77
The Mitochondrial Peptidase Pitrilysin Degrades Islet Amyloid Polypeptide in Beta-Cells. PLoS One (2015) 0.75
Amylin: what might be its role in Alzheimer's disease and how could this affect therapy? Expert Rev Proteomics (2013) 0.75
The Effects of Lipid Membranes, Crowding and Osmolytes on the Aggregation, and Fibrillation Propensity of Human IAPP. J Diabetes Res (2015) 0.75
Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation. Int J Mol Sci (2016) 0.75
Atomic structures of fibrillar segments of hIAPP suggest tightly mated β-sheets are important for cytotoxicity. Elife (2017) 0.75
On the Environmental Factors Affecting the Structural and Cytotoxic Properties of IAPP Peptides. J Diabetes Res (2015) 0.75
Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice. Front Endocrinol (Lausanne) (2016) 0.75
Influence of Aluminium and EGCG on Fibrillation and Aggregation of Human Islet Amyloid Polypeptide. J Diabetes Res (2016) 0.75
Selenium-enriched Spirulina protects INS-1E pancreatic beta cells from human islet amyloid polypeptide-induced apoptosis through suppression of ROS-mediated mitochondrial dysfunction and PI3/AKT pathway. Eur J Nutr (2014) 0.75
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 16.62
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes (2008) 5.23
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology (2011) 4.99
Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem (2004) 4.33
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem (2007) 3.42
Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem (2002) 3.37
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes (2007) 2.96
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev (2008) 2.79
The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab (2007) 2.72
Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes (2009) 2.62
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care (2006) 2.46
Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A (2004) 2.32
Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology (2006) 2.27
Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes (2004) 2.20
β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care (2012) 2.20
Maternal smoking during pregnancy and regional brain volumes in preterm infants. J Pediatr (2009) 2.19
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes (2009) 2.10
Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J Biol Chem (2006) 2.09
Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care (2006) 2.03
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med (2009) 1.99
Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes (2006) 1.87
Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab (2011) 1.83
Induction of endoplasmic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated proteins by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab (2007) 1.80
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes (2005) 1.73
Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol (2006) 1.72
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener (2011) 1.67
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes (2007) 1.57
Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem (2008) 1.56
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab (2009) 1.55
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Preparation and characterization of neurotoxic tau oligomers. Biochemistry (2010) 1.53
Cognitive and neuropsychological outcomes at 5 years of age in preterm children born in the 2000s. Dev Med Child Neurol (2010) 1.49
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2005) 1.49
Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab (2006) 1.47
Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J (2006) 1.45
GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care (2010) 1.45
Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44
NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci (2005) 1.44
Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest (2006) 1.43
Rb and p130 control cell cycle gene silencing to maintain the postmitotic phenotype in cardiac myocytes. J Cell Biol (2011) 1.42
Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes (2006) 1.40
Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. Proc Natl Acad Sci U S A (2012) 1.39
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity. J Clin Invest (2014) 1.37
A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci (2009) 1.36
Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth. Trends Endocrinol Metab (2010) 1.33
Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol (2009) 1.33
Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes (2012) 1.32